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or organs to restore impaired function resulting from any cause, 
including congenital defects, disease, trauma and aging. It uses a 
combination of several technological approaches that moves it be-
yond traditional transplantation and replacement therapies. These 
approaches may include, but are not limited to, the use of soluble 
molecules, gene therapy, stem cell transplantation, tissue engineer-
ing and reprogramming of cell and tissue types’. 
The interdisciplinarity of TERM goes far beyond medical sci-
ences such as transplantation, immunology, and stem cell biology. 
It rather integrates disciplines such as system biology, nanotech-
nology, material science, genetics, and bioengineering in an effort 
to restore or replace organs and their function. However, spectacu-
lar successes in experimental settings, such as cloning of mammali-
ans, the discovery of human embryonic stem cells and finally the 
reprogramming of terminally differentiated cells into various body 
cells via induced pluripotent stem cells [11–15], ignited hope and 
overreaching expectations of scientific and lay auditorium leading 
Time magazine to claim tissue engineer as being ‘The Hottest Job’ 
for the future [16]. By 2000, there were 66 companies in the USA 
working in the field and having a capital value of USD 2.5 billion 
[16]. In the meantime, failures in early applications and mature 
understanding of (patho)biology of diseased or deteriorated tissue 
have fostered new and holistic concepts of TERM: Regenerative 
technologies and services strive to boost innate repair processes 
and provide scalable production and standardized application of 
clinical grade biotherapeutics. Critical areas include regulatory 
pathways for RM therapies, strategic partnerships, coordination of 
resources, developing of standards, priorities for industry, 
biobanking, and integration of new technologies [17, 18]. Accord-
ing to the US Department of Health and Human Services, RM of-
fers the potential to cure countless fatal and debilitating conditions 
through therapies that spur in vivo regeneration and in vitro crea-
tion of healthy tissue for implantation [19]. In the prospect, 7 of 10 
deaths in the world will be caused by non-communicable diseases, 
Uncountable dreams, myths and excitements on artificial gen-
eration of tissues, organs, and even whole organisms accompany 
mankind’s history to master health and disease. The creation of 
Eve out of Adam’s rip, the generation of Prometheus without sex-
ual reproduction in the Greek mythology, and the failing trial by 
Doctor Faustus in Goethe’s poetry to build a living Homunculus 
illustrate the desire of mankind to overcome sickness and perisha-
bility [1]. With the emergence of empirical sciences during and 
after the Enlightenment era, the physicochemical understanding of 
man and his failures led to the discoveries of modern developmen-
tal biology [2], which were culminating in seismic achievements 
such as cloning of the sheep Dolly, growing of a human ear on a 
mouse – the so-called auriculosaurus – or the isolation of omnipo-
tent human embryonic stem cells [2, 3]. Although tissue engineer-
ing (TE) and regenerative medicine (RM) – often reflected by the 
acronym ‘TERM’ – are used synonymously and interchangeably in 
literature, the two areas of medical science pursue different focus 
and at the same time are complementary to each other [4]. TE goes 
back to early work by Vacanti, Langer, Green, Matapurkar and 
many others, combining in vitro isolated and expanded organ-spe-
cific cells in co-existence with artificial biodegradable matrix scaf-
folds to replace diseased, defect or missing organ tissue such as 
bone, cartilage, liver, ureter and others in attempt to generate in 
vivo engineered (induced) organ tissue [5–8]. Publications on TE 
started to appear as early as 1990 while the more comprehensive 
entity of RM appeared in the literature only by 2000 and thereafter 
[9]. There are many, ever changing definitions of RM in the litera-
ture reflecting evolving science and technologies involved but also 
taking care of society’s needs driven by population growth and de-
mographic changes. One of the most comprehensive outline of 
 today’s RM is given by Greenwood et al. [10] in 2006 which covers 
also the progresses made since then: ‘Regenerative Medicine is an 
emerging interdisciplinary field of research and clinical application 
focused on the repair, replacement or regeneration of cells, tissue 
Received: July 15, 2016
Accepted: July 18, 2016
Published online: July 26, 2016
Dr. Beat M. Frey
Blood Transfusion Service Zurich
Rütistrasse 19
8952 Zurich-Schlieren, Switzerland
bm.frey@zhbsd.ch
© 2016 S. Karger GmbH, Freiburg
1660–3796/16/0434–0244$39.50/0
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
2 
- 1
1/
10
/2
01
6 
1:
21
:0
6 
PM
Stem Cell Factories – the Rebirth of Tissue 
Engineering and Regenerative Medicine 
Transfus Med Hemother 2016;43:244–246 245
and by 2030 the most prevalent chronic conditions responsible for 
morbidity and mortality will be cardiovascular diseases, cancer, 
diabetes, and respiratory diseases [20]. Medical progress, robust 
success in combating life-threatening acute conditions, and demo-
graphic changes are the main reasons for these megatrends. Tradi-
tional health care approaches will be overburdened either by lim-
ited resources, restricted applicability or treatment related side 
 effects [20]. Strategies for therapeutic repair as offered by TERM 
now rely on the ‘R3’ paradigm [21]: Replacement of tissue by trans-
plantation, regeneration of tissue by stem cell engraftment, and re-
juvenation of resident cells by cell activation with the ultimate goal 
of ‘restitutio ad integrum’. 
In the upcoming two special issues of Transfusion Medicine 
and Hemotherapy we provide overviews on TERM activities of 
various medical specialties. The first three manuscripts describe 
properties and application of stem cells isolated from anatomically 
not defined organs such as hematopoietic and mesenchymal cells 
as well as adipose tissue [22–24]. Besides immune modulatory 
 effects executed by these cells, they might transdifferentiate into 
functional cells replacing and/or regenerating organ-specific tissue. 
The following manuscripts describe organ-residing stem cells 
which can be (re-)activated and used for repair of structural and 
functional deficiencies of the heart [25–27], bone [28], brain [29], 
bladder [30], and teeth [31] as examples. Also logistic, regulatory 
and safety issues for extensively in vitro manipulated cells will be 
addressed in the last two manuscripts by Hartmann-Fritsch et al. 
[32] and Simeon-Dubach et al. [33].
The purpose of TERM is to bridge advances in stem cell biology 
with individualized disease management [21] by integration of new 
physicobiological approaches such as mechanobiology and chip 
technology [34, 35]. However, convincing clinical studies on 
TERM products and procedures providing adequate power and 
credibility are urgently needed [36] to reinforce TERM on the 
 marketplace of health care and life science industry. Learning from 
the past [37], strategic exchange of experts [38], financing and 
 returns of innovations [39, 40], and regulatory issues [41] will be 
the ingredients to make TERM driving. After decades of hopes and 
hypes, TERM is about to embark into a new era to deliver mature, 
integrative, and holistic health care services designed for cure of 
disease considering individual regenerative capacity [42].
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